US equities |
NVDA $241.55 ▲+1.11% SPCX $174.11 ▲+1.77% MU $1,065.64 ▲+0.16% AMD $655.60 ▲+3.78% MRVL $291.68 ▲+7.53% SNDK $1,672.73 ▼-1.84% AVGO $378.13 ▲+4.31% TSLA $380.54 ▲+0.48%
FinancialContent

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

2.220 -0.020 (-0.89%)
Delayed Quote Updated: 11:32 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
EXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program ↗
The United States Patent and Trademark Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program.  
Via Benzinga
News headline image
BioRestorative Therapies: This Biopharma Company Is Helping Your Body Heal Itself ↗
Lance Alstodt, Chairman and CEO of BioRestorative Therapies, Inc. (NASDAQ: BRTX), was recently interviewed by Benzinga.  
Via Benzinga
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
By Julian Richard, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
News headline image
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes 
Via News Direct
Topics Intellectual Property
News headline image
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes ↗
BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a... 
Via Benzinga
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program
Via Investor Brand Network
Topics Intellectual Property
News headline image
EXCLUSIVE: BioRestorative Poised To Receive European Patent For ThermoStem Program ↗
The European Patent Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program.  The notice of allowance was... 
Via Benzinga
News headline image
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results 
Via News Direct
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
By Julian Richard, Benzinga 
Via TheNewswire.com
News headline image
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony... 
Via Benzinga
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
News headline image
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies 
Via News Direct
News headline image
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
Via Benzinga
News headline image
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
From BioRestorative Therapies, Inc
Via GlobeNewswire
News headline image
EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development... 
Via Benzinga
News headline image
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
From BioRestorative Therapies, Inc
Via GlobeNewswire
News headline image
EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease ↗
BioRestorative Therapies, Inc (NASDAQ: BRTX), a stem cell-based therapies clinical-stage company, forged an agreement with Regenexx, LLC, under which BRTX gets exclusive license rights for intellectual... 
Via Benzinga
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
From BioRestorative Therapies, Inc
Via GlobeNewswire
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
By Faith Ashmore, Benzinga 
Via News Direct
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes. 
Via TheNewswire.com
News headline image
The NIH Has Given BioRestorative Therapies A Stamp Of Approval ↗
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.  
Via Benzinga
News headline image
See What's Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies! ↗
While stem cell therapy has always been a more controversial topic, as the general public has gained more knowledge on the practice and induced pluripotent stem (iPS) cells have gained traction in... 
Via Benzinga
News headline image
BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show
From BioRestorative Therapies, Inc
Via GlobeNewswire
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
Via TheNewswire.com
News headline image
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
By David Willey, Benzinga 
Via News Direct
News headline image
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field ↗
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
Via Benzinga
News headline image
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >